News

BMJ1d
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there is no widely used definition of remission that is stringent but achievable and could be applied uniformly ...
BMJ1d
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Objectives To compare over 2 years the safety, efficacy and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients with rheumatoid ...
BMJ2d
Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study
4 National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing, China Objectives To evaluate the associations of regular glucosamine use with all-cause and ...
BMJ2d
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology ...
1 School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, UK 2 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, UK Correspondence to ...
BMJ5d
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled ...
Objective To compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil cytoplasm antibody ...
BMJ5d
Update of EULAR recommendations for the treatment of systemic sclerosis
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the ...
BMJ5d
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
Correspondence to Dr Elizabeth R Volkmann, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; evolkmann{at}mednet.ucla.edu ...
BMJ6d
Bone destruction in arthritis
Department of Medicine, Beth Israel Deaconess Medical Center, New England Baptist Bone and Joint Institute, Harvard Institutes of Medicine, 4 Blackfan Circle, Room 241, Boston, MA 02115, USA ...
BMJ6d
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
Objectives To investigate how individual rheumatoid arthritis (RA) autoantibodies associate with individual signs and symptoms at the time of RA diagnosis. Methods IgA, IgG, IgM rheumatoid factor (RF) ...
BMJ6d
Diagnostic values of clinical diagnostic tests in subacromial impingement syndrome
OBJECTIVE Subacromial impingement syndrome (SIS) is a frequent cause of shoulder pain. The aim of this study was to investigate the diagnostic values of clinical diagnostic tests, in patients with SIS ...
BMJ6d
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Objectives We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and ...
BMJ7d
Leflunomide: mode of action in the treatment of rheumatoid arthritis
a Academic Ziekenhuis Leiden, Stafcentrum Reumatologie, Leiden, The Netherlands, b Division of Immunology and Allergy, Geneva University Hospital, Geneva, Switzerland Professor F C Breedveld, Academic ...